Biocryst Pharmaceuticals, Inc.
5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 4 name spellings.
12
Ending by 2030
Feb 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for Imidazole-Containing Inhibitors of ALK2 Kinase (US 11,661,426) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
- 2 fees due Dec 25 to 27, 2026 · next Dec 25
- 3 fees due Jan 25, 2027
- 1 fee due Mar 24, 2027The maintenance fee for Methods and Compositions for Inhibition of Polymerase (US 10,420,769) comes due Mar 24, 2027. Unpaid by Sep 24, 2027, it lapses early.
- 1 fee due May 7, 2027The maintenance fee for Human Plasma Kallikrein Inhibitors (US 11,807,605) comes due May 7, 2027. Unpaid by Nov 8, 2027, it lapses early.
- 1 fee due Jul 9, 2027The maintenance fee for Substituted Benzofuran, Benzopyrrole, Benzothiophene, and Structurally Related Complement Inhibitors (US 11,866,418) comes due Jul 9, 2027. Unpaid by Jan 10, 2028, it lapses early.
- 1 fee due Aug 18, 2027The maintenance fee for Human Plasma Kallikrein Inhibitors (US 10,562,850) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
- 1 fee due Oct 28, 2027The maintenance fee for Human Plasma Kallikrein Inhibitors (US 10,633,345) comes due Oct 28, 2027. Unpaid by Apr 28, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,770,427 | Antiviral Treatments In force · Low confidence | In force | Low confidence | |
| US 10,391,075 | Antiviral Treatments In force · Low confidence | In force | Low confidence | |
| US 11,464,755 | Antiviral Treatments In force · Low confidence | In force | Low confidence | |
| US 12,121,503 | Antiviral Treatments In force · Low confidence | In force | Low confidence | |
| US 7,514,410 | Hepatitis C Therapies In force · High confidence | In force | High confidence | |
| US 8,163,703 | Hepatitis C Therapies In force · High confidence | In force | High confidence | |
| US 8,778,997 | Antiviral Treatments In force · Medium confidence | In force | Medium confidence | |
| US 8,344,132 | Methods for the Preparation of 9-Deazapurine Derivatives In force · High confidence | In force | High confidence | |
| US 8,242,085 | Tetrahydrofuro [3,4-d] Dioxolane Compounds for Use in the Treatment of Viral Infections and Cancer In force · High confidence | In force | High confidence | |
| US 8,440,813 | Antiviral Nucleoside Analogs In force · High confidence | In force | High confidence |
Also on record, not counted in the 61: 5 patents in force now held by others · 4 lapsed for an unpaid fee · 31 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
8 pending · 22 abandoned · 3 no status recorded